Cipla Receives US FDA Approval for Generic Advair Diskus

Cipla Limited, along with its subsidiary Cipla USA Inc., announced on July 27, 2026, that it has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder). Key Highlights: Strengths Approved: All three strengths (100/50 mcg, 250/50 mcg, and 500/50 mcg). Indication: Management of asthma and Chronic Obstructive Pulmonary Disease (COPD). Market Opportunity: Targets a substantial US market estimated at approximately $908 million (per IQVIA). Launch Timeline: Expected in Q2 of FY 2026-27. Strategic Significance: This approval marks a major milestone as it is Cipla’s first dry powder inhaler (DPI) approval originating from its US-based manufacturing network (New York facility). It validates the company's vertically integrated inhalation platform and demonstrates its capability to develop, scale, and manufacture complex respiratory therapies locally in the United States. Outlook: The approval reinforces Cipla's legacy as a global leader in respiratory care. By leveraging its differentiated US manufacturing capabilities, Cipla is well-positioned to capture a meaningful share of this high-value, competitive market while ensuring a reliable, high-quality supply for American patients. $CIPLA